Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Nuclear Medicine and Molecular Imaging
Erschienen in: Nuclear Medicine and Molecular Imaging 2/2020

19.04.2020 | Review

Preclinical Voxel-Based Dosimetry in Theranostics: a Review

verfasst von: Arun Gupta, Min Sun Lee, Joong Hyun Kim, Dong Soo Lee, Jae Sung Lee

Erschienen in: Nuclear Medicine and Molecular Imaging | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Due to the increasing use of preclinical targeted radionuclide therapy (TRT) studies for the development of novel theranostic agents, several studies have been performed to accurately estimate absorbed doses to mice at the voxel level using reference mouse phantoms and Monte Carlo (MC) simulations. Accurate dosimetry is important in preclinical theranostics to interpret radiobiological dose-response relationships and to translate results for clinical use. Direct MC (DMC) simulation is believed to produce more realistic voxel-level dose distribution with high precision because tissue heterogeneities and nonuniform source distributions in patients or animals are considered. Although MC simulation is considered to be an accurate method for voxel-based absorbed dose calculations, it is time-consuming, computationally demanding, and often impractical in daily practice. In this review, we focus on the current status of voxel-based dosimetry methods applied in preclinical theranostics and discuss the need for accurate and fast voxel-based dosimetry methods for pretherapy absorbed dose calculations to optimize the dose computation time in preclinical TRT.
Literatur
1.
Lewis JS, Achilefu S, Garbow JR, Laforest R, Welch MJ. Small animal imaging: current technology and perspectives for oncological imaging. Eur J Cancer. 2002;38:2173–88.PubMedCrossRef
2.
Grassi R, Cavaliere C, Cozzolino S, Mansi L, Cirillo S, Tedeschi G, et al. Small animal imaging facility: new perspectives for the radiologist. Radiol Med. 2009;114:152–67.PubMedCrossRef
3.
Dash A, Chakraborty S, Pillai MRA, Knapp FF. Peptide receptor radionuclide therapy: an overview. Cancer Biother Radiopharm. 2015;30:47–71.PubMedCrossRef
4.
Flux G, Bardies M, Monsieurs M, Savolainen S, Strand SE, Lassmann M. The impact of PET and SPECT on dosimetry for targeted radionuclide therapy. Z Med Phys. 2006;16:47–59.PubMedCrossRef
5.
de Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar M, van Gameren A, et al. [177Lu-DOTA0,Tyr3]octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer. 2001;92:628–33.PubMedCrossRef
6.
Pool SE, Krenning EP, Koning GA, van Eijck CH, Teunissen JJ, Kam B, et al. Preclinical and clinical studies of peptide receptor radionuclide therapy. Semin Nucl Med. 2010;40(3):209–18.PubMedCrossRef
7.
Paganelli G, Sansovini M, Ambrosetti A, Severi S, Monti M, Scarpi E, et al. 177Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study. Eur J Nucl Med Mol Imaging. 2014;41:1845–51.PubMedCrossRef
8.
Kost SD. Patient-specific dosimetry for targeted radionuclide therapy using deformable anthropomorphic phantoms: Vanderbilt University; 2015.
9.
10.
Giblin MF, Veerendra B, Smith CJ. Radiometallation of receptor-specific peptides for diagnosis and treatment of human cancer. In Vivo. 2005;19:9–29.PubMed
11.
de Jong M, Breeman WA, Kwekkeboom DJ, Valkema R, Krenning EP. Tumor imaging and therapy using radiolabeled somatostatin analogues. Acc Chem Res. 2009;42:873–80.PubMedCrossRef
12.
Müller C, Struthers H, Winiger C, Zhernosekov K, Schibli R. DOTA conjugate with an albumin-binding entity enables the first folic acid–targeted 177Lu-radionuclide tumor therapy in mice. J Nucl Med. 2013;54:124–31.PubMedCrossRef
13.
Birn H, Spiegelstein O, Christensen EI, Finnell RH. Renal tubular reabsorption of folate mediated by folate binding protein 1. J Am Soc Nephrol. 2005;16:608–15.PubMedCrossRef
14.
Holm J, Hansen SI, Høier-Madsen M, Bostad L. A high-affinity folate binding protein in proximal tubule cells of human kidney. Kidney Int. 1992;41:50–5.PubMedCrossRef
15.
Sandoval RM, Kennedy MD, Low PS, Molitoris BA. Uptake and trafficking of fluorescent conjugates of folic acid in intact kidney determined using intravital two-photon microscopy. Am J Phys Cell Phys. 2004;287:C517.CrossRef
16.
Kolbert KS, Watson T, Matei C, Xu S, Koutcher JA, Sgouros G. Murine S factors for liver, spleen, and kidney. J Nucl Med. 2003;44:784–91.PubMed
17.
Theodora K, Panagiotis P, George L, George CK. A preclinical simulated dataset of S -values and investigation of the impact of rescaled organ masses using the MOBY phantom. Phys Med Biol. 2016;61:2333.CrossRef
18.
Strigari L, Konijnenberg M, Chiesa C, Bardies M, Du Y, Gleisner KS, et al. The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy. Eur J Nucl Med Mol Imaging. 2014;41:1976–88.PubMedCrossRef
19.
Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med. 2006;47:1467–75.PubMed
20.
Cremonesi M, Ferrari M, Di Dia A, Botta F, De Cicco C, Bodei L, et al. Recent issues on dosimetry and radiobiology for peptide receptor radionuclide therapy. Q J Nucl Med Mol Imaging. 2011;55:155–67.PubMed
21.
Stabin MG, Brill AB. State of the art in nuclear medicine dose assessment. Semin Nucl Med. 2008;38:308–20.PubMedCrossRef
22.
Funk T, Sun M, Hasegawa BH. Radiation dose estimate in small animal SPECT and PET. Med Phys. 2004;31:2680–6.PubMedCrossRef
23.
Mauxion T, Barbet J, Suhard J, Pouget J-P, Poirot M, Bardiès M. Improved realism of hybrid mouse models may not be sufficient to generate reference dosimetric data. Med Phys. 2013;40:052501.PubMedCrossRef
24.
Larsson E, Ljungberg M, Strand S-E, Jönsson B-A. Monte Carlo calculations of absorbed doses in tumours using a modified MOBY mouse phantom for pre-clinical dosimetry studies. Acta Oncol. 2011;50:973–80.PubMedCrossRef
25.
Dewaraja YK, Wilderman SJ, Ljungberg M, Koral KF, Zasadny K, Kaminiski MS. Accurate dosimetry in (131)I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation. J Nucl Med. 2005;46:840–9.PubMedPubMedCentral
26.
Dewaraja YK, Frey EC, Sgouros G, Brill AB, Roberson P, Zanzonico PB, et al. MIRD pamphlet no. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy. J Nucl Med. 2012;53:1310–25.PubMedPubMedCentralCrossRef
27.
Flynn AA, Green AJ, Pedley RB, Boxer GM, Boden R, Begent RHJ. A mouse model for calculating the absorbed beta-particle dose from 131I- and 90Y-labeled immunoconjugates, including a method for dealing with heterogeneity in kidney and tumor. Radiat Res. 2001;156:28–35.PubMedCrossRef
28.
Edmond Hui T, Fisher DR, Kuhn JA, Williams LE, Nourigat C, Badger CC, et al. A mouse model for calculating cross-organ beta doses from yttrium-90-labeled immunoconjugates. Cancer. 1994;73:951–7.CrossRef
29.
Bolch WE, Bouchet LG, Robertson JS, Wessels BW, et al. MIRD pamphlet no, 17: the dosimetry of nonuniform activity distributions--radionuclide S-values at the voxel level. J Nucl Med. 1999;40:11S–36S.PubMed
30.
Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD pamphlet no. 21: a generalized Schema for radiopharmaceutical dosimetry—standardization of nomenclature. J Nucl Med. 2009;50:477–84.PubMedCrossRef
31.
32.
33.
Lee DS, Im H-J, Lee Y-S. Radionanomedicine: widened perspectives of molecular theragnosis. Nanomedicine. 2015;11:795–810.PubMedCrossRef
34.
Tolmachev V, Orlova A, Pehrson R, Galli J, Baastrup B, Andersson K, et al. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res. 2007;67:2773.PubMedCrossRef
35.
Franc BL, Acton PD, Mari C, Hasegawa BH. Small-animal SPECT and SPECT/CT: important tools for preclinical investigation. J Nucl Med. 2008;49:1651–63.PubMedCrossRef
36.
Habraken JBA, de Bruin K, Shehata M, Booij J, Bennink R, van Eck Smit BLF, et al. Evaluation of high-resolution pinhole SPECT using a small rotating animal. J Nucl Med. 2001;42:1863–9.PubMed
37.
Blankenberg FG, Strauss HW. Nuclear medicine applications in molecular imaging. J Magn Reson Imaging. 2002;16:352–61.PubMedCrossRef
38.
Schäfers KP. Imaging small animals with positron emission tomography. Nuklearmedizin. 2003;42:86–9.PubMedCrossRef
39.
Cheng D, Wang Y, Liu X, Pretorius PH, Liang M, Rusckowski M, et al. Comparison of 18F PET and 99mTc SPECT imaging in phantoms and in tumored mice. Bioconjug Chem. 2010;21:1565–70.PubMedPubMedCentralCrossRef
40.
Del Guerra A, Belcari N. State-of-the-art of PET, SPECT and CT for small animal imaging. Nucl Instrum Methods Phys Res A. 2007;583:119–24.CrossRef
41.
Andrew BH, Benjamin LF, Grant TG, Bruce HH. Assessment of the sources of error affecting the quantitative accuracy of SPECT imaging in small animals. Phys Med Biol. 2008;53:2233.CrossRef
42.
Freek JB, Brendan V. Design and simulation of a high-resolution stationary SPECT system for small animals. Phys Med Biol. 2004;49:4579.CrossRef
43.
Schramm NU, Ebel G, Engeland U, Schurrat T, Behe M, Behr TM. High-resolution SPECT using multipinhole collimation. IEEE Trans Nucl Sci. 2003;50:315–20.CrossRef
44.
Schramm N, Hoppin J, Lackas C, Gershman B, Norenberg J, de Jong M. Improving resolution, sensitivity and applications for the NanoSPECT/CT: a high-performance SPECT/CT imager for small-animal research. J Nucl Med. 2007;48:436P.
45.
Frank PD. Design and performance of a multi-pinhole collimation device for small animal imaging with clinical SPECT and SPECT–CT scanners. Phys Med Biol. 2008;53:4185.CrossRef
46.
Finucane CM, Murray I, Sosabowski JK, Foster JM, Mather SJ. Quantitative accuracy of low-count SPECT imaging in phantom and in vivo mouse studies. Int J Mol Imaging. 2011;2011:8.CrossRef
47.
Gupta A, Kim KY, Hwang D, Lee MS, Lee DS, Lee JS. Performance evaluation and quantitative accuracy of multipinhole NanoSPECT/CT scanner for theranostic Lu-177 imaging. J Korean Phys Soc. 2018;72:1379–86.CrossRef
48.
Li T, Ao ECI, Lambert B, Brans B, Vandenberghe S, Mok GSP. Quantitative imaging for targeted radionuclide therapy dosimetry - technical review. Theranostics. 2017;7:4551–65.PubMedPubMedCentralCrossRef
49.
Vilchis-Juárez A, Ferro-Flores G, Santos-Cuevas C, Morales-Avila E, Ocampo-García B, Díaz-Nieto L, et al. Molecular targeting radiotherapy with cyclo-RGDfK(C) peptides conjugated to 177Lu-labeled gold nanoparticles in tumor-bearing mice. J Biomed Nanotechnol. 2014;10:393–404.PubMedCrossRef
50.
Loevinger R, Budinger TF, Watson EE, Society of Nuclear Medicine. Medical internal radiation dose C. MIRD Primer for Absorbed Dose Calculations: Society of Nuclear Medicine; 1988.
51.
Stabin MG, Eckerman KF, Bolch WE, Bouchet LG, Patton PW. Evolution and status of bone and marrow dose models. Cancer Biother Radiopharm. 2002;17:427–33.PubMedCrossRef
52.
Boutaleb S, Pouget JP, Hindorf C, Pelegrin A, Barbet J, Kotzki PO, et al. Impact of mouse model on preclinical dosimetry in targeted radionuclide therapy. Proc IEEE. 2009;97:2076–85.CrossRef
53.
Muthuswamy MS, Roberson PL, Buchsbaum DJ. A mouse bone marrow dosimetry model. J Nucl Med. 1998;39:1243–7.PubMed
54.
Miller WH, Hartmann-Siantar C, Fisher D, Descalle M-A, Daly T, Lehmann J, et al. Evaluation of beta-absorbed fractions in a mouse model for 90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu radionuclides. Cancer Biother Radiopharm. 2005;20:436–49.PubMedCrossRef
55.
Hindorf C, Ljungberg M, Strand S-E. Evaluation of parameters influencing S values in mouse dosimetry. J Nucl Med. 2004;45:1960–5.PubMed
56.
Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 1996;37:538–46.PubMed
57.
Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023–7.PubMed
58.
Stabin MG, Konijnenberg MW. Re-evaluation of absorbed fractions for photons and electrons in spheres of various sizes. J Nucl Med. 2000;41:149–60.PubMed
59.
Parach AA, Rajabi H, Askari MA. Assessment of MIRD data for internal dosimetry using the GATE Monte Carlo code. Radiat Environ Biophys. 2011;50:441–50.PubMedCrossRef
60.
Lanconelli N, Pacilio M, Meo SL, Botta F, Dia AD, Aroche LAT, et al. A free database of radionuclide voxel S values for the dosimetry of nonuniform activity distributions. Phys Med Biol. 2012;57:517–33.PubMedCrossRef
61.
Stabin MG, Peterson TE, Holburn GE, Emmons MA. Voxel-based mouse and rat models for internal dose calculations. J Nucl Med. 2006;47:655–9.PubMed
62.
Dogdas B, Stout D, Chatziioannou, Leahy RM. Digimouse: a 3D whole body mouse atlas from CT and cryosection data. Phys Med Biol. 2007;52:577–87.PubMedPubMedCentralCrossRef
63.
Bitar A, Lisbona A, Bardiès M. S-factor calculations for mouse models using Monte-Carlo simulations. Q J Nucl Med Mol Imaging. 2007;51:343–51.PubMed
64.
Bitar A, Lisbona A, Thedrez P, Sai Maurel C, Le Forestier D, Barbet J, et al. A voxel-based mouse for internal dose calculations using Monte Carlo simulations (MCNP). Phys Med Biol. 2007;52:1013–25.PubMedCrossRef
65.
Bednarz B, Grudzinski J, Marsh I, Besemer A, Baiu D, Weichert J, et al. Murine-specific internal dosimetry for preclinical investigations of imaging and therapeutic agents. Health Phys. 2018;114:450–9.PubMedPubMedCentralCrossRef
66.
Kim CH, Yeom YS, Nguyen TT, Han MC, Choi C, Lee H, Han H, Shin B, Lee J-K, Kim HS, Zankl M, Petoussi-Henss N, Bolch WE, Lee C, Chung BS, Qiu R, Eckerman K. New mesh-type phantoms and their dosimetric applications, including emergencies. Ann ICRP. 2018;47(3–4):45–62.
67.
Segars WP, Tsui BMW, Frey EC, Johnson GA, Berr SS. Development of a 4-D digital mouse phantom for molecular imaging research. Mol Imaging Biol. 2004;6:149–59.PubMedCrossRef
68.
Segars W, Tsui B. 4D MOBY and NCAT phantoms for medical imaging simulation of mice and men. J Nucl Med. 2007;48:203P.
69.
70.
Xie T, Zaidi H. Monte Carlo-based evaluation of S-values in mouse models for positron-emitting radionuclides. Phys Med Biol. 2013;58:169–82.PubMedCrossRef
71.
Larsson E, Strand S-E, Ljungberg M, Jönsson B-A. Mouse S-factors based on Monte Carlo simulations in the anatomical realistic Moby phantom for internal dosimetry. Cancer Biother Radiopharm. 2007;22:438–42.PubMedCrossRef
72.
Taschereau R, Chatziioannou AF. Monte Carlo simulations of absorbed dose in a mouse phantom from 18-fluorine compounds. Med Phys. 2007;34:1026–36.PubMedPubMedCentralCrossRef
73.
74.
Buckley LA, Kawrakow I, Rogers DW. An EGSnrc investigation of cavity theory for ion chambers measuring air kerma. Med Phys. 2003;30:1211–8.PubMedCrossRef
75.
Hendricks JS, Adam KJ, Booth TE, Briesmeister JF, Carter LL, Cox LJ, et al. Present and future capabilities of MCNP. Appl Radiat Isot. 2000;53:857–61.PubMedCrossRef
76.
77.
Allison J, Amako K, Apostolakis JE, Araujo HA, Dubois PA, Asai MA, et al. Geant4 developments and applications. IEEE Trans Nucl Sci. 2006;53:270–8.CrossRef
78.
Sarrut D, Bardiès M, Boussion N, Freud N, Jan S, Létang JM, et al. A review of the use and potential of the GATE Monte Carlo simulation code for radiation therapy and dosimetry applications. Med Phys. 2014;41:064301.PubMedCrossRef
79.
Berger MJ. Distribution of absorbed dose around point sources of electrons and beta particles in water and other media. Washington: National Bureau of Standards; 1971.
80.
Seltzer SM. Electron-photon Monte Carlo calculations: the ETRAN code. Int J Rad Appl Instrum A. 1991;42:917–41.CrossRef
81.
Prideaux AR, Song H, Hobbs RF, He B, Frey EC, Ladenson PW, et al. Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry. J Nucl Med. 2007;48:1008–16.PubMedPubMedCentralCrossRef
82.
Sgouros G, Frey E, Wahl R, He B, Prideaux A, Hobbs R. Three-dimensional imaging-based radiobiological dosimetry. Semin Nucl Med. 2008;38:321–34.PubMedPubMedCentralCrossRef
83.
Dewaraja YK, Schipper MJ, Roberson PL, Wilderman SJ, Amro H, Regan DD, et al. 131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling. J Nucl Med. 2010;51:1155–62.PubMedPubMedCentralCrossRef
84.
Hobbs RF, Wahl RL, Lodge MA, Javadi MS, Cho SY, Chien DT, et al. 124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison. J Nucl Med. 2009;50:1844–7.PubMedPubMedCentralCrossRef
85.
Kolbert KS, Sgouros G, Scott AM, Bronstein JE, Malane RA, Zhang J, et al. Implementation and evaluation of patient-specific three-dimensional internal dosimetry. J Nucl Med. 1997;38:301–7.PubMed
86.
Guy MJ, Flux GD, Papavasileiou P, Flower MA, Ott RJ. RMDP: a dedicated package for 131I SPECT quantification, registration and patient-specific dosimetry. Cancer Biother Radiopharm. 2003;18:61–9.PubMedCrossRef
87.
Gardin I, Bouchet LG, Assié K, Caron J, Lisbona A, Ferrer L, et al. Voxeldose: a computer program for 3-D dose calculation in therapeutic nuclear medicine. Cancer Biother Radiopharm. 2003;18:109–15.PubMedCrossRef
88.
Wilderman S, Dewaraja Y. Method for fast CT/SPECT-based 3D Monte Carlo absorbed dose computations in internal emitter therapy. IEEE Trans Nucl Sci. 2007;54:146–51.PubMedPubMedCentralCrossRef
89.
Marcatili S, Pettinato C, Daniels S, Lewis G, Edwards P, Fanti S, et al. Development and validation of RAYDOSE: a Geant4-based application for molecular radiotherapy. Phys Med Biol. 2013;58:2491.PubMedCrossRef
90.
Kost SD, Dewaraja YK, Abramson RG, Stabin MG. VIDA: a voxel-based dosimetry method for targeted radionuclide therapy using Geant4. Cancer Biother Radiopharm. 2015;30:16–26.PubMedPubMedCentralCrossRef
91.
Jan S, Benoit D, Becheva E, Carlier T, Cassol F, Descourt P, et al. GATE V6: a major enhancement of the GATE simulation platform enabling modelling of CT and radiotherapy. Phys Med Biol. 2011;56:881.PubMedCrossRef
92.
Perrot Y, Degoul F, Auzeloux P, Bonnet M, Cachin F, Chezal JM, et al. Internal dosimetry through GATE simulations of preclinical radiotherapy using a melanin-targeting ligand. Phys Med Biol. 2014;59:2183.PubMedCrossRef
93.
Gupta A, Lee MS, Kim JH, Park S, Park HS, Kim SE, et al. Preclinical voxel-based dosimetry through GATE Monte Carlo simulation using PET/CT imaging of mice. Phys Med Biol. 2019;64:095007.PubMedCrossRef
94.
Brechbiel MW. Targeted alpha-therapy: past, present, future? Dalton Trans. 2007;43:4918–28.CrossRef
95.
Haberkorn U, Giesel F, Morgenstern A, Kratochwil C. The future of radioligand therapy: α, β, or both? J Nucl Med. 2017;58:1017–8.PubMedCrossRef
96.
Milenic DE, Brady ED, Brechbiel MW. Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov. 2004;3:488–99.PubMedCrossRef
97.
Mendoza-Nava H, Ferro-Flores G, Ramirez FD, Ocampo-Garcia B, Santos-Cuevas C, Aranda-Lara L, et al. 177Lu-dendrimer conjugated to folate and bombesin with gold nanoparticles in the dendritic cavity: a potential theranostic radiopharmaceutical. J Nanomater. 2016;2016:11.CrossRef
98.
Kim K, Kim S-J. Lu-177-based peptide receptor radionuclide therapy for advanced neuroendocrine tumors. Nucl Med Mol Imaging. 2018;52:208–15.PubMedCrossRef
99.
100.
Pratt EC, Shaffer TM, Grimm J. Nanoparticles and radiotracers: advances toward radionanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016;8:872–90.PubMedPubMedCentralCrossRef
101.
Ritt P, Vija H, Hornegger J, Kuwert T. Absolute quantification in SPECT. Eur J Nucl Med Mol Imaging. 2011;38:S69–77.PubMedCrossRef
102.
103.
Mezzenga E, D’Errico V, D’Arienzo M, Strigari L, Panagiota K, Matteucci F, et al. Quantitative accuracy of 177Lu SPECT imaging for molecular radiotherapy. PLoS One. 2017;12:e0182888.PubMedPubMedCentralCrossRef
104.
Hong KJ, Choi Y, Lee SC, Lee SY, Song TY, Min BJ, et al. A compact SPECT/CT system for small animal imaging. IEEE Trans Nucl Sci. 2006;53:2601–4.CrossRef
105.
Stabin MG. Update: the case for patient-specific dosimetry in radionuclide therapy. Cancer Biother Radiopharm. 2008;23:273–84.PubMedCrossRef
106.
Ilan E, Sandström M, Wassberg C, Sundin A, Garske-Román U, Eriksson B, et al. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE. J Nucl Med. 2015;56:177–82.PubMedCrossRef
107.
Agostinelli S, Allison J, Amako K, Apostolakis J, Araujo H, Arce P, et al. Geant4—a simulation toolkit. Nucl Instrum Methods Phys Res A. 2003;506:250–303.CrossRef
108.
Shcherbinin S, Piwowarska-Bilska H, Celler A, Birkenfeld B. Quantitative SPECT/CT reconstruction for 177Lu and 177Lu/ 90Y targeted radionuclide therapies. Phys Med Biol. 2012;57:5733.PubMedCrossRef
109.
Haller S, Reber J, Brandt S, Bernhardt P, Groehn V, Schibli R, et al. Folate receptor-targeted radionuclide therapy: preclinical investigation of anti-tumor effects and potential radionephropathy. Nucl Med Biol. 2015;42:770–9.PubMedCrossRef
110.
Kuo HT, Merkens H, Zhang Z, Uribe CF, Lau J, Zhang C, et al. Enhancing treatment efficacy of 177Lu-PSMA-617 with the conjugation of an albumin-binding motif: preclinical dosimetry and endoradiotherapy studies. Mol Pharm. 2018;15:5183–91.PubMedCrossRef
111.
Timmermand OV, Elgqvist J, Beattie KA, Örbom A, Larsson E, Eriksson SE, et al. Preclinical efficacy of hK2 targeted [177Lu] hu11B6 for prostate cancer theranostics. Theranostics. 2019;9:2129.PubMedPubMedCentralCrossRef
112.
Gupta A, Shin JH, Lee MS, Park JY, Kim K, Kim JH, et al. Voxel-based dosimetry of iron oxide nanoparticle-conjugated 177Lu-labeled folic acid using SPECT/CT imaging of mice. Mol Pharm. 2019;16:1498–506.PubMedCrossRef
113.
Furhang EE, Chui C-S, Sgouros G. A Monte Carlo approach to patient-specific dosimetry. Med Phys. 1996;23:1523–9.PubMedCrossRef
114.
Zaidi H. Relevance of accurate Monte Carlo modeling in nuclear medical imaging. Med Phys. 1999;26:574–608.PubMedCrossRef
115.
Loudos G, Tsougos I, Boukis S, Karakatsanis N, Georgoulias P, Theodorou K, et al. A radionuclide dosimetry toolkit based on material-specific Monte Carlo dose kernels. Nucl Med Commun. 2009;30:504–12.PubMedCrossRef
116.
Dieudonné A, Hobbs RF, Lebtahi R, Maurel F, Baechler S, Wahl RL, et al. Study of the impact of tissue density heterogeneities on 3-dimensional abdominal dosimetry: comparison between dose kernel convolution and direct Monte Carlo methods. J Nucl Med. 2013;54:236–43.PubMedCrossRef
117.
Hippeläinen E, Tenhunen M, Sohlberg A. Fast voxel-level dosimetry for 177Lu labelled peptide treatments. Phys Med Biol. 2015;60:6685.PubMedCrossRef
118.
Khazaee Moghadam M, Kamali Asl A, Geramifar P, Zaidi H. Evaluating the application of tissue-specific dose kernels instead of water dose kernels in internal dosimetry: a Monte Carlo Study. Cancer Biother Radiopharm. 2016;31:367–79.PubMedCrossRef
119.
Lee MS, Kim JH, Paeng JC, Kang KW, Jeong JM, Lee DS, et al. Whole-body voxel-based personalized dosimetry: the multiple voxel S-value approach for heterogeneous media with nonuniform activity distributions. J Nucl Med. 2018;59:1133–9.PubMedCrossRef
120.
Lee MS, Hwang D, Kim JH, Lee JS. Deep-dose: a voxel dose estimation method using deep convolutional neural network for personalized internal dosimetry. Sci Rep. 2019;9:10308.PubMedPubMedCentralCrossRef
121.
Hwang D, Kang SK, Kim KY, Seo S, Paeng JC, Lee DS, et al. Generation of PET attenuation map for whole-body time-of-flight 18F-FDG PET/MRI using a deep neural network trained with simultaneously reconstructed activity and attenuation maps. J Nucl Med. 2019;60:1183–9.PubMedPubMedCentralCrossRef
122.
Park J, Hwang D, Kim KY, Kang SK, Kim YK, Lee JS. Computed tomography super-resolution using deep convolutional neural network. Phys Med Biol. 2018;63:145011.PubMedCrossRef
123.
Hwang D, Kim KY, Kang SK, Seo S, Paeng JC, Lee DS, et al. Improving the accuracy of simultaneously reconstructed activity and attenuation maps using deep learning. J Nucl Med. 2018;59:1624–9.PubMedCrossRef
124.
Kang SK, Seo S, Shin SA, Byun MS, Lee DY, Kim YK, et al. Adaptive template generation for amyloid PET using a deep learning approach. Hum Brain Mapp. 2018;39:3769–78.PubMedCrossRef
125.
Hegazy MAA, Cho MH, Cho MH, Lee SY. U-net based metal segmentation on projection domain for metal artifact reduction in dental CT. Biomed Eng Lett. 2019;9:375–85.PubMedPubMedCentralCrossRef
126.
Mansour RF. Deep-learning-based automatic computer-aided diagnosis system for diabetic retinopathy. Biomed Eng Lett. 2018;8:41–57.PubMedCrossRef
127.
Cicone F, Gnesin S, Denoël T, Stora T, van der Meulen NP, Müller C, et al. Internal radiation dosimetry of a 152Tb-labeled antibody in tumor-bearing mice. EJNMMI Res. 2019;9:53.PubMedPubMedCentralCrossRef
128.
Sivapackiam J, Laforest R, Sharma V. 68Ga[Ga]-Galmydar: biodistribution and radiation dosimetry studies in rodents. Nucl Med Biol. 2018;59:29–35.PubMedCrossRef
129.
Maina T, Konijnenberg MW, KolencPeitl P, Garnuszek P, Nock BA, Kaloudi A, et al. Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with 111In-CP04 in medullary thyroid carcinoma patients. Eur J Pharm Sci. 2016;91:236–42.PubMedPubMedCentralCrossRef
130.
Hino-Shishikura A, Suzuki A, Minamimoto R, Shizukuishi K, Oka T, Tateishi U, et al. Biodistribution and radiation dosimetry of [18F]-5-fluorouracil. Appl Radiat Isot. 2013;75:11–7.PubMedCrossRef
131.
Repetto-Llamazares AH, Larsen RH, Mollatt C, Lassmann M, Dahle J. Biodistribution and dosimetry of 177Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma. Curr Radiopharm. 2013;6:20–7.PubMedPubMedCentralCrossRef
132.
Sakata M, Oda K, Toyohara J, Ishii K, Nariai T, Ishiwata K. Direct comparison of radiation dosimetry of six PET tracers using human whole-body imaging and murine biodistribution studies. Ann Nucl Med. 2013;27:285–96.PubMedCrossRef
133.
Stabin MG. Fundamentals of nuclear medicine dosimetry. Springer Science & Business Media; 2008.
Metadaten
Titel
Preclinical Voxel-Based Dosimetry in Theranostics: a Review
verfasst von
Arun Gupta
Min Sun Lee
Joong Hyun Kim
Dong Soo Lee
Jae Sung Lee
Publikationsdatum
19.04.2020
Verlag
Springer Singapore
Erschienen in
Nuclear Medicine and Molecular Imaging / Ausgabe 2/2020
Print ISSN: 1869-3474
Elektronische ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-020-00640-z

Weitere Artikel der Ausgabe 2/2020

Nuclear Medicine and Molecular Imaging 2/2020 Zur Ausgabe

Review

New Frontiers in Molecular Imaging with Superparamagnetic Iron Oxide Nanoparticles (SPIONs): Efficacy, Toxicity, and Future Applications

Original Article

Radioactivity Reduction of 2-Deoxy-2-[18F] Fluoro-D-Glucose by Milk and Ursodeoxycholic Acid in Preclinical Study

Perspective

Sleep and Neuroimaging

Original Article

First In-Human Medical Imaging with a PASylated 89Zr-Labeled Anti-HER2 Fab-Fragment in a Patient with Metastatic Breast Cancer

Interesting Image

Renal Potassium Excretion Visualized on 82Rubidium PET/CT

Review

From Theranostics to Immunotheranostics: the Concept